natgillin/translations-raw huggingface dataset:
Empliciti (mg/kg) Intravenous
Empliciti (mg/kg) intravensko
Empliciti + Lenalidomide and Dexamethasone
Empliciti + lenalidomid in deksametazon
Empliciti + Lenalidomide/ Dexamethasone N = 321
Empliciti + lenalidomid/ deksametazon N = 321
Empliciti 300 mg powder for concentrate elotuzumab
Empliciti 300 mg prašek za koncentrat elotuzumab
Empliciti 300 mg powder for concentrate for solution for infusion Each vial contains 300 mg elotuzumab*.
Empliciti 300 mg prašek za koncentrat za raztopino za infundiranje Ena viala vsebuje 300 mg elotuzumaba*.
Empliciti 300 mg powder for concentrate for solution for infusion Empliciti 400 mg powder for concentrate for solution for infusion
Empliciti 300 mg prašek za koncentrat za raztopino za infundiranje Empliciti 400 mg prašek za koncentrat za raztopino za infundiranje
Empliciti 400 mg powder for concentrate elotuzumab
Empliciti 400 mg prašek za koncentrat elotuzumab
Empliciti contains the active substance elotuzumab, which is a monoclonal antibody, a type of protein designed to recognise and attach to a specific target substance in the body.
Zdravilna učinkovina zdravila Empliciti je elotuzumab, monoklonsko protitelo, vrsta beljakovine, ki prepozna in se pritrdi na posebno ciljno mesto v telesu.
Empliciti contains the active substance elotuzumab.
Zdravilo Empliciti vsebuje zdravilno učinkovino elotuzumab.
Empliciti has been associated with infusion reactions (see section 2 “Warnings and precautions”).
Uporaba zdravila Empliciti je bila povezana z infuzijskimi reakcijami (glejte poglavje 2 “Opozorila in previdnostni ukrepi”).
Empliciti is a medicine for treating multiple myeloma (a cancer of the bone marrow).
Empliciti je zdravilo za zdravljenje multiplega mieloma (rak kostnega mozga).
Empliciti is for intravenous use only.
Zdravilo Empliciti je namenjeno samo za intravensko uporabo.
Empliciti is not recommended for use in children and adolescents aged under 18 years.
Pri otrocih in mladostnikih, mlajših od 18 let, uporaba zdravila Empliciti ni priporočljiva.
Empliciti is taken in treatment cycles that are 28 days (4 weeks) long in combination with lenalidomide and dexamethasone.
Zdravljenje z zdravilom Empliciti poteka v ciklih, ki so dolgi 28 dni (4 tedne), v kombinaciji z lenalidomidom in deksametazonom.
Empliciti is unlikely to affect your ability to drive or use machines.
Verjetnost vpliva zdravila Empliciti na sposobnost upravljanja vozil in strojev je majhna.
Empliciti is used when you have already had at least one multiple myeloma treatment before.
Zdravilo Empliciti uporabljamo pri bolnikih, ko so se zaradi multiplega mieloma predhodno že zdravili z vsaj eno obliko zdravljenja.
Empliciti should be initiated at an infusion rate of 0.5 mL/min.
Infundiranje zdravila Empliciti je treba začeti s hitrostjo infundiranja 0,5 ml/min.
Empliciti should be inspected visually for particulate matter and discolouration prior to administration.
Zdravilo Empliciti pred aplikacijo preglejte glede morebitne prisotnosti trdnih delcev ali spremembe barve.
Empliciti should not be used in women of childbearing potential, unless the clinical condition of the woman requires treatment with elotuzumab.
Zdravila Empliciti se ne sme uporabljati pri ženskah v rodni dobi, razen če klinično stanje ženske zahteva zdravljenje z elotuzumabom.
Empty all contents of each sahet into the mixing bottle
Vsebino vsake vrečice v celoti stresite v mešalno plastenko.
Empty cartridges must not be refilled and must be properly discarded.
Praznih vložkov ne smete znova polniti, pač pa jih je treba ustrezno zavreči.
Empty metering pump must be discarded in accordance with local requirements.
Prazno odmerno črpalko morate odstraniti skladno z lokalnimi predpisi.
Empty pens must never be re-used and must be properly discarded.
Praznih injekcijskih peresnikov se nikdar ne sme uporabiti in jih je treba ustrezno zavreči.
Empty pens must never be reused and must be properly discarded.
Praznih injekcijskih peresnikov se nikoli ne sme ponovno uporabiti in jih je treba pravilno zavreči.
Empty pens must not be re-filled and must be properly discarded.
Praznih peresnikov ne smete znova napolniti, pač pa jih je treba ustrezno zavreči.
Empty the contents of the syringe in a glass of water by pushing the piston into the syringe (figure ).
Brizgo spraznite v kozarec vode tako, da potisnete bat v brizgo (slika ).
Empty the contents of the syringe in a glass of water or baby’s bottle by pushing the piston to the bottom of the syringe (figure 7).
Vsebino brizge spraznite v kozarec vode ali v steklenico za hranjenje otrok tako, da potisnete bat navzdol (slika 7).
Empty the correct amount of Rapamune from the syringe into only a glass or plastic container with at least 60 mL of water or orange juice.
Vsebino brizge izpraznimo v steklen ali plastičen kozarček, v katerem je najmanj 60 ml vode ali pomarančnega soka.
Empty the syringe
Izpraznite brizgo
Empty the water into the mixing bottle.
Vodo izbrizgajte v mešalno plastenko.
Empty vials, antiseptic wipes, and other supplies can be disposed of in your garbage.
Prazne viale, zložence in druge pripomočke lahko zavržete med gospodinjske odpadke.
Empty water into open mixing bottle
Vodo izbrizgajte v odprto mešalno plastenko.
EMR 62 202-007: This randomised study in patients with metastatic colorectal cancer after failure of irinotecan-based treatment for metastatic disease as the last treatment before study entry compared the combination of cetuximab and irinotecan (218 patients) with cetuximab monotherapy (111 patients).
EMR 62 202-007: v tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom po neuspešnem zdravljenju metastatske bolezni z irinotekanom kot zadnjim zdravljenjem pred vstopom v študijo primerjali kombinacijo cetuksimaba in irinotekana (218 bolnikov) s samostojnim cetuksimabom (111 bolnikov).
Emselex 15 mg once daily
Emselex 15 mg enkrat na dan
Emselex 15 mg prolonged-release tablets
Emselex 15 mg tablete s podaljšanim sproščanjem
Emselex 15 mg prolonged-release tablets are round, convex light peach tablets and are debossed with “DF” on one side and “15” on the other.
Emselex 15 mg tablete s podaljšanim sproščanjem so okrogle, konveksne tablete svetlo breskove barve z vtisnjenim napisom “DF” na eni strani in “15”na drugi
Emselex 7.5 mg prolonged-release tablets
Emselex 7,5 mg tablete s podaljšanim sproščanjem
Emselex 7.5 mg prolonged-release tablets are round, convex white tablets and are debossed with “DF” on one side and “7.5” on the other.
Emselex 7,5 mg tablete s podaljšanim sproščanjem so okrogle, konveksne bele tablete, ki imajo na eni strani vtisnjen napis “DF”, na drugi pa “7.5”.
Emselex is contraindicated in patients with:
Emselex je kontraindiciran pri bolnikih:
Emselex is not recommended during pregnancy.
Zdravila Emselex ne uporabljajte med nosečnostjo.
Emselex is not recommended for use in children.
Uporaba zdravila Emselex pri otrocih ni priporočljiva.
emtansine.
emtanzin.
Emtricitabine (200 mg once daily)
emtricitabine (200 mg enkrat
Emtricitabine (200 mg once daily) Elvitegravir (50 mg once daily) Ritonavir (100 mg once daily)
dnevno) elvitegravir (50 mg enkrat dnevno)
Emtricitabine +tenofovir alafenamide
emtricitabin + alafenamidtenofovirat
Emtricitabine / t enofovir disoproxil / efavirenz
Emtricitabin / di zoproksiltenofo virat / efavirenz
Emtricitabine / tenofovir disoproxil / efavirenz*
Emtricitabin / dizoproksiltenof ovirat / efavirenz
Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture.
Emtricitabin in alafenamidtenofovirat sta pokazala sinergijsko protivirusno aktivnost v celični kulturi.
Emtricitabine and tenofovir are eliminated by renal excretion and the exposure to emtricitabine and tenofovir increases in individuals with renal dysfunction (see sections 4.4 and 5.2).
Emtricitabin in tenofovir se izločata preko ledvic in pri posameznikih z ledvično disfunkcijo izpostavljenost emtricitabinu in tenofovirju naraste (glejte poglavji 4.4 in 5.2).
Emtricitabine and tenofovir disoproxil fumarate: A moderate amount of data on pregnant women (between 300-1,000 pregnancy outcomes) indicates no malformations or foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil fumarate.
Emtricitabin in dizoproksiltenofovirijev fumarat: Manjše število podatkov o uporabi pri nosečnicah (med 300 in 1000 izpostavljenih nosečnosti) kaže, da ni povezave med uporabo emtricitabina in dizoproksiltenofovirijevega fumarata in malformacijsko ali feto-/neonatalno toksičnostjo.
Emtricitabine and tenofovir individually and in combination have shown activity against HBV in pharmacodynamic studies (see section 5.1).
Emtricitabin in tenofovir sta v študijah farmakodinamike posamično in v kombinaciji pokazala aktivnost proti virusu HBV (glejte poglavje 5.1).
emtricitabine and tipranavir
emtricitabin in tipranavir
Emtricitabine dose (mg)
Odmerek emtricitabina (mg)
Emtricitabine exposure may be markedly increased in patients with severe renal insufficiency (creatinine clearance < 30 ml/min) receiving daily doses of 200 mg emtricitabine as hard capsules or 240 mg as the oral solution.
Izpostavljenost emtricitabinu se lahko pomembno poveča pri bolnikih z resno ledvično insuficienco (očistek kreatinina < 30 ml/min), ki prejemajo dnevni odmerek 200 mg emtricitabina v obliki trdih kapsul ali 240 mg v obliki peroralne raztopine.
Emtricitabine in combination with other antiretroviral agents, including nucleoside analogues, non-nucleoside analogues and protease inhibitors, has been shown to be effective in the treatment of HIV infection in treatment-naïve patients and treatment-experienced patients with stable virological control.
Emtricitabin, v kombinaciji z drugimi protiretrovirusnimi učinkovinami, vključno z analogi nukleozidov in učinkovinami, ki niso analogi nukleozidov ter zaviralci proteaz, se je izkazal za učinkovito zdravilo pri zdravljenju okužbe z virusom HIV pri bolnikih, ki se zdravijo prvič in pri bolnikih, ki se zdravijo že dalj časa in imajo stabilno stanje virusa v telesu.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and analogue of 2’-deoxycytidine.
Emtricitabin je nukleozidni zaviralec reverzne transkriptaze (NRTI-nucleoside reverse transcriptase inhibitor) in analog 2’-deoksicitidina.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2’-deoxycytidine.
Emtricitabin je nukleozidni zaviralec reverzne transkriptaze (nucleoside reverse transcriptase inhibitor, NRTI) in nukleozidni analog 2’-deoksicitidina.
Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus (HBV).
Emtricitabin je sintetični nukleozidni analog citidina z učinkovanjem, ki je specifično humanemu virusu zmanjšane imunosti (HIV-1 in HIV-2) in virusu hepatitisa B (HBV).
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%).
Emtricitabin se primarno izloča preko ledvic – celoten odmerek se izolira iz urina (približno 86 %) in iz blata (približno 14 %).
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%).
Emtricitabin se primarno izloča preko ledvic – celoten odmerek se izolira iz urina (približno 86%) in iz blata (približno 14%).
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%).
Emtricitabin se primarno izloča skozi ledvica – celoten odmerek se izloči z urinom (približno 86 %) in blatom (približno 14 %).
Emtricitabine is principally eliminated by renal excretion and the exposure to emtricitabine increases in patients with renal impairment.
Emtricitabin se v glavnem izloča prek ledvic, izpostavljenost emtricitabinu pa se poveča pri bolnikih z ledvično okvaro.
Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 reverse transcriptase, resulting in DNA chain termination.
Emtricitabin trifosfat in tenofovir difosfat kompetitivno inhibirata HIV- 1 reverzno transkriptazo, kar rezultira v prekinitvi verige DNA.
Emtricitabine triphosphate competitively inhibits HIV-1 reverse transcriptase (RT), resulting in DNA chain termination.
Emtricitabin trifosfat kompetitivno zavira reverzno transkriptazo (RT) HIV-1, kar povzroči prekinitev verige DNA.
Emtricitabine+ tenofovir disoproxil fumarate+efavirenz
Emtricitabin+ dizoproksiltenofovirijev fumarat+efavirenz
Emtricitabine+ tenofovir disoproxil fumarate+efavirenz*
Emtricitabin+ dizoproksiltenofovirije v fumarat+efavirenz
Emtricitabine+tenofovir alafenamide containing regimen (n = 333)
Režim, ki vsebuje emtricitabin+alafenamidtenofovirat (n = 333)
Emtricitabine+tenofovir alafenamide containing regimens
Režimi, ki vsebujejo emtricitabin + alafenamidtenofovirat
Emtricitabine+tenofovir alafenamide regimen
Režim, ki vsebuje emtricitabin + alafenamidtenofovirat
Emtricitabine- resistant viruses with the M184V/I mutation were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir and zidovudine.
Virusi odporni na emtricitabin z mutacijo M184V/I so bili navzkrižno odporni na lamivudin, a so ohranili občutljivost za didanozin, stavudin, tenofovir in zidovudin.
Emtricitabine-resistant viruses were cross-resistant to lamivudine, but retained sensitivity to other nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine, stavudine, tenofovir, abacavir and didanosine), all non-nucleoside reverse transcriptase inhibitors (NNRTIs) and all protease inhibitors (PIs).
Virusi odporni na emtricitabin, so bili navzkrižno odporni na lamivudin, a so ohranili občutljivost za druge nukleozidne zaviralce reverzne transkriptaze (NRTI, nucleoside reverse transcriptase inhibitors) (zidovudin, stavudin, tenofovir, abacavir in didanozin), na vse ne-nukleozidne zaviralce reverzne transkriptaze (NNRTI, non-nucleoside reverse transcriptase inhibitors) in vse zaviralce proteaz (PI, protease inhibitors).
emtricitabine/
citabin/dizopro
emtricitabine/
citabin/tenofovi
Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate (200/ 25/ 300 mg once daily)/ sofosbuvir/ velpatasvir (400/ 100 mg once daily)c, d
Emtricitabin/rilpivirin/dizoprok- siltenofovirijev fumarat (200/25/300 mg enkrat na dan)/sofosbuvir/velpatasvir (400/100 mg enkrat na dan)c, d
emtricitabine/tenofovir and
potrebna za
Emtricitabine/tenofovir disoproxil fumarate + rilpivirine hydrochloride has been shown to be non-inferior in achieving HIV-1 RNA < 50 copies/mL compared to emtricitabine/tenofovir disoproxil fumarate + efavirenz.
Pokazalo se je, da emtricitabin/dizoproksiltenofovirijev fumarat + rilpivirinijevim kloridom nista slabša pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z emtricitabinom/dizoproksiltenofovirijevim fumaratom + efavirenzom.
Emtricitabine/tenofovir disoproxil has not been studied in individuals over the age of 65.
Emtricitabina/dizoproksiltenofovirata niso proučevali pri posameznikih, starejših od 65 let.
Emtricitabine/Tenofovir disoproxil Zentiva 200 mg / 245 mg film-coated tablets
Emtricitabin/dizoproksiltenofovirat Zentiva 200 mg/245 mg filmsko obložene tablete
Emtricitabine/Tenofovir disoproxil Zentiva [outer packaging only]
Emtricitabin/dizoproksiltenofovirat Zentiva [samo na zunanji ovojnini]
Emtricitabine/Tenofovir disoproxil Zentiva can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva se lahko jemlje namesto emtricitabina in dizoproksiltenofovirata, ki se uporabljata ločeno v enakih odmerkih.
Emtricitabine/Tenofovir disoproxil Zentiva can cause dizziness.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva lahko povzroči omotičnost.
Emtricitabine/Tenofovir disoproxil Zentiva contains two active substances, emtricitabine and tenofovir disoproxil.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva vsebuje dve zdravilni učinkovini, emtricitabin in dizoproksiltenofovirat.
Emtricitabine/Tenofovir disoproxil Zentiva has not been studied in patients over 65 years of age.
Emtricitabin/dizoproksiltenofovirat Zentiva niso proučevali pri bolnikih, starejših od 65 let.
Emtricitabine/Tenofovir disoproxil Zentiva is not for use in children and adolescents under 18 years of age.
Zdravila Emtricitabin/dizoproksiltenofovirat Zentiva ne smejo uporabljati otroci in mladostniki, mlajši od 18 let.
Emtricitabine/tenofovir disoproxil Zentiva is not recommended because appropriate dose reductions cannot be achieved with the combination tablet.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva se ne priporoča, ker ustreznega znižanja odmerka ni mogoče doseči s kombinirano tableto.
Emtricitabine/Tenofovir disoproxil Zentiva is not recommended in this population (see section 4.2).
Uporaba zdravila Emtricitabin/dizoproksiltenofovirat Zentiva pri tej populaciji ni priporočljiva (glejte poglavje 4.2).
Emtricitabine/Tenofovir disoproxil Zentiva is used to treat Human Immunodeficiency Virus 1(HIV-1) infection, in adults aged 18 years and over.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva se uporablja za zdravljenje okužbe z virusom HIV–1 (virus človeške imunske pomanjkljivosti 1) pri odraslih, starih 18 let in več.
Emtricitabine/Tenofovir disoproxil Zentiva may affect your kidneys.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva ima lahko vpliv na ledvice.
Emtricitabine/Tenofovir disoproxil Zentiva should always be used combined with other medicines to treat HIV infection.
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva je treba vedno uporabljati v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV.
Emtricitabine/Tenofovir disoproxil Zentiva should not be administered concomitantly with adefovir dipivoxil.
Zdravila Emtricitabin/dizoproksiltenofovirat Zentiva se ne sme sočasno uporabljati z dipivoksiladefoviratom.
Emtricitabine/Tenofovir disoproxil Zentiva should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4).
Zdravila Emtricitabin/dizoproksiltenofovirat Zentiva se ne sme sočasno uporabljati z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat, alafenamidtenofovirat ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.4).
Emtricitabine/Tenofovir disoproxil Zentiva should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5).
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva se ne sme dajati skupaj z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat, alafenamidtenofovirat ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.5).
Emtricitabine/Tenofovir disoproxil Zentiva tablets can be disintegrated in approximately 100 ml of water, orange juice or grape juice and taken immediately.
Tableto Emtricitabin/dizoproksiltenofovirat Zentiva se lahko raztopi v približno 100 ml vode, pomarančnega ali grozdnega soka.
Emtricitabine/Tenofovir disoproxil Zentiva with food and drink
Zdravilo Emtricitabin/dizoproksiltenofovirat Zentiva skupaj s hrano in pijačo
Emtricitabine:
Cmin: n/i emtricitabin:
Emtricitabine:
Cmin: n/i tenofovir:
Emtricitabine:
efavirenz:
Emtricitabine:
tenofovir:
Emtricitabine:
To kombinacijo je treba
emtricitabine: If your child is taking emtricitabine your child’s kidney function should be checked before initiation of Aptivus.
Emtricitabin: Če vaš otrok jemlje emtricitabin, je treba vašemu otroku opraviti preiskavo ledvičnega delovanja, preden bo začel jemati zdravilo Aptivus.
Emtriva 10 mg/ml oral solution
Emtriva 10 mg/ml peroralna raztopina
Emtriva 10 mg/ml oral solution Emtricitabine
Emtriva 10 mg/ml peroralna raztopina emtricitabin
Emtriva 10 mg/ml oral solution may be taken with or without food.
Emtriva 10 mg/ml peroralna raztopina se lahko jemlje s hrano ali brez.
Emtriva 10 mg/ml oral solution should be taken once daily, orally with or without food.
Zdravilo Emtriva 10 mg/ml perorala raztopina se jemlje enkrat dnevno, peroralno, s hrano ali brez.
Emtriva 200 mg hard capsules are only suitable for patients who weigh at least 33 kg.
Emtriva 200 mg trde kapsule so primerne le za bolnike, ki tehtajo najmanj 33 kg.
Emtriva 200 mg hard capsules should be taken once daily, orally with or without food.
Zdravilo Emtriva 200 mg trde kapsule se jemljejo enkrat dnevno, peroralno, s hrano ali brez.
Emtriva can be taken with or without food.
Bolnik lahko zdravilo Emtriva vzame s hrano ali brez nje.
Emtriva does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Emtriva ne ozdravi okužbe s HIV ali AIDS-a, lahko pa podaljša čas do nastopa poškodb imunskega sistema in razvoja okužb ter bolezni, ki so povezane z AIDS-om.
Emtriva hard capsules have a white opaque body with a light blue opaque cap.
Emtriva trde kapsule imajo belo neprosojno telo s svetlo modrim neprosojnim pokrovčkom.
Emtriva has been studied in three main studies including 1,498 HIV-infected adults.
Zdravilo Emtriva so raziskovali v treh glavnih študijah, ki so skupaj vključevale 1498 odraslih bolnikov, okuženih s HIV.
Emtriva is a medicine containing the active substance emtricitabine.
Emtriva je zdravilo, ki vsebuje zdravilno učinkovino emtricitabin.
Emtriva is a treatment for Human Immunodeficiency Virus (HIV) infection in adults, children and infants aged 4 months and over.
Zdravilo Emtriva se uporablja za zdravljenje okuţbe z virusom HIV pri odraslih, otrocih in dojenčkih, starih 4 mesece ali več.
Emtriva is also available as a 10 mg/ml oral solution for use in infants aged 4 months and over, children and patients who are unable to swallow hard capsules and patients with renal insufficiency.
Zdravilo Emtriva je pri dojenčkih, starih 4 mesece ali več, otrocih in bolnikih, ki ne morejo pogoltniti trdih kapsul ter bolnikih z ledvično insuficienco na voljo tudi v obliki 10 mg/ml peroralne raztopine.
Emtriva is an antiviral medicine.
Zdravilo Emtriva je protivirusno zdravilo.
Emtriva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and children aged 4 months and over.
Zdravilo Emtriva v kombinaciji z drugimi protiretrovirusnimi zdravili je indicirano za zdravljenje odraslih in otrok, starih 4 mesece in več, okuženih z virusom HIV-1.
Emtriva may cause dizziness.
Zdravilo Emtriva lahko povzroči omotico.
Emtriva oral solution contains Sunset Yellow (E110) which may cause allergic reactions, methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).
Emtriva peroralna raztopina vsebuje oranžno FCF (E110), ki lahko povzroči alergijske reakcije, metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216), ki tudi lahko povzročita alergijske rekacije (lahko zapoznele).
Emtriva oral solution is a clear, orange to dark orange solution that comes in bottles containing 170 ml with a measuring cup.
Peroralna raztopina Emtriva je prozorna tekočina, oranžne do temno oranžne barve, na voljo v 170 ml plastenki skupaj z merico.
Emtriva oral solution is available for people who have difficulty in swallowing Emtriva hard capsules.
Peroralna raztopina Emtriva je na voljo za bolnike, ki imajo težave s požiranjem trdih kapsul Emtriva.
Emtriva should not be taken with any other medicinal products containing emtricitabine or medicinal products containing lamivudine.
Zdravila Emtriva se ne sme jemati z nobenimi drugimi zdravili, ki vsebujejo emtricitabin ali zdravili, ki vsebujejo lamivudin.
Emtriva should not be used in people who may be hypersensitive (allergic) to emtricitabine or to any of the other ingredients.
Zdravila Emtriva ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) emtricitabin ali katero koli drugo sestavino zdravila.